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ABSTRACT 
 
The no-reflow phenomenon (NRp), a dreaded complication 
of primary and also of any complex percutaneous coronary 
intervention (PCI), is characterized by insufficient myocardial 
perfusion in a territory of a coronary artery without evidence of 
mechanical obstruction. Microvascular injury is the underlying 
mechanism of NRp and its manifestation is not only impaired 
TIMI flow (<3), but also impaired TIMI myocardial perfusion 
grade (TMPG) which should be assessed in case of chest pain, 
persistent ST segment elevation or hemodynamic compromise 
despite the presence of TIMI III flow. The NRp mechanism is 
multifaceted, the evidence base for its treatment is inconsistent 
and limited, but its predictors are well known. The 
armamentarium against NRp consists of preventive and 
therapeutic strategies, both mechanical and pharmacological. A 
brief overview of all the above issues concerning NRp is 
attempted herein. Rhythmos 2019;14(2):27-30. 
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Introduction 
  
Myocardial infarction (MI) and acute coronary 
syndromes in general remain principal causes of mortality 
despite major treatment advances during the last decades. 
Coronary artery reperfusion by percutaneous coronary 
intervention (PCI) represents the cornerstone of the current 
therapeutic approach since it contributes to decreasing the 
infarct size and improving prognosis. However, despite the 
rapid recanalization of epicardial arteries that are 
responsible for initial ischemia there may still persist 
perfusion anomalies at the level of microcirculation that 
are sometimes responsible for the dreaded no-reflow 
phenomenon (NRp), which is characterised by inadequate 
myocardial perfusion in a coronary artery territory without 
angiographic evidence of vessel obstruction.1 
   
Pathophysiology of no-reflow phenomenon 
 
The NRp exact pathophysiology has not been yet 
totally elucidated despite the fact that it had been initially 
described for the first time in an experimental myocardial 
infarction model in dogs more than forty years ago.2 
Multiple mechanisms seem to be in action in order to 
induce a perfusion defect (Fig. 1).  Ischemia-reperfusion 
injury lesions related directly to the reopening of the 
culprit artery are implicated, as well as a systemic 
inflammatory reaction with neutrophil infiltrates, a tissue 
edema because of increased vascular permeability that is 
responsible for extravascular compression and narrowing 
of the microvessels lumen, a component of coronary 
spasm, as well as distal intravascular microemboli at the 
moment of reperfusion. 
 
Figure 1. No-reflow phenomenon pathophysiology. 
  
No-Reflow: Clinical Implications 
 
The diagnosis and treatment of NRp are currently a 
central element of the interventional treatment of acute MI 
due to its prognostic impact at short and long term. 
Actually the presence of NRp is directly correlated to a 
more extensive necrosis area due to the MI, more severe 
left ventricular dysfunction, increased risk for cardiac 
rhythm disorders and constitutes an independent 
prognostic factor for heart failure, rehospitalization, 
recurrent MI and a cardiovascular mortality risk multiplied 
by a factor of 5.3,4 Thus being a major risk factor NRp must 
be promptly recognized among patients with MI. Multiple 
predictors for the occurrence of NRp have been identified, 
such as primary PCI with possible multiple distal emboli, 
a long ischemic time, an extensive ischemic zone such as 
in case of proximal left anterior descending (LAD) 
occlusion, a large thrombus burden, a high neutrophil 
count, the presence of diabetes, the absence of pre-
conditioning, e.tc. .5  
 
No-Reflow: Diagnosis 
 
The means to diagnose NRp are relatively limited and 
well defined. The first among them and mostly used is the 
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TIMI flow, which permits the assessment of the quality of 
reperfusion of the culprit artery during primary PCI (Table 
1).6 NRp  is defined by a flow <3 at the end of the 
procedure. The TIMI flow assessment is convenient and 
straightforward but gives limited information concerning 
only the epicardial arteries but not the microcirculation. It 
should be coupled with TIMI myocardial perfusion (blush) 
grade (TMPG), which more specifically evaluates the 
clearance of the contrast medium from the myocardium 
and thus the myocardial perfusion and the microcirculation 
function.  As with TIMI flow it is graded from 0 to 3 (Table 
2).7 The NRp is defined by a MBG <2.  Beyond 
angiographic scores the electrocardiogram holds a central 
role in MI after revascularization through the assessment 
of ST segment resolution 90 minutes after reperfusion. In 
case of an ST segment resolution less than 50-70% an 
“electric” NRp is diagnosed.  A combination of the above 
criteria allows for a most accurate assessment of the 
reperfusion quality and the patient prognosis. When only 
TIMI score is used as a criterion NRp is found in 7% of 
acute MI patients, while when TBG and the ST segment 
resolution are used after revascularization NRp is detected 
in 65% of them.5  
  
Table 1. TIMI flow classification. 
 
TIMI flow grade 
 
 
0 Total coronary obstruction. 
 
I Slow flow, not opacifying totally the 
coronary artery. 
 
II Slow flow, totally opacifying the 
coronary artery. 
 
III Normal flow.  
   
Table 2. TIMI myocardial perfusion grade (TMPG) 
classification. 
 
Therefore, it seems that NRp is rather frequent and has 
major clinical implications, but unfortunately it can be 
underestimated and undetected due to imperfect diagnostic 
tools. The advent of magnetic resonance imaging (MRI) 
for the myocardium has permitted a significant progress in 
NRp diagnosis, since it offers a direct evaluation of 
myocardial perfusion and the microcirculation and 
actually holds the position of a true gold standard.  NRp is 
defined by a delay of myocardial perfusion during the three 
first minutes after the gadolinium injection and is 
interpreted by a zone of low signal during the initial 
acquisition phase. Being a highly sensitive and 
noninvasive exam MRI carries the advantage of being able 
to be performed at a distance from the MI event. It has been 
shown that NRp is a progressive and dynamic phenomenon 
possibly extending up to 48 hours after the MI.8 Thus it is 
recommended to wait for at least 2 days before performing 
a myocardial MRI after a coronary occlusion in order not 
to underestimate the extent of NRp.   
 
No-Reflow: Treatment  
 
Due to the multiple mechanisms that are implicated in 
its pathophysiology NRp treatment has many aspects . 
(Fig. 2).  
 
 
Figure 2. No-reflow phenomenon mechanisms and respective 
preventive and therapeutic measures. 
 
- Preventive measures: During the acute MI phase 
thrombus aspiration coupled with intracoronary 
administration of GPIIb/IIIa antagonists has demonstrated 
its benefit on blush score  in TAPAS study.9 However, a 
benefit has not been confirmed concerning hard clinical 
endpoints in TASTE and TOTAL multicentre studies and 
routine thrombus aspiration during primary PCI is not 
supported by current guidelines.10,11 On the other hand 
there does not exist to that day a potential effect of the 
novel potent P2Y12 inhibitors (prasugrel and ticagrelor) on 
the NRp.  
TIMI myocardial 
perfusion (blush) 
grade (TMPG) 
 
0 Failure of contrast medium to enter the 
microcirculation 
 
I Contrast agent slowly enters but fails to 
exit from the microcirculation  
 
II Slow entry and delayed exit of contrast 
medium from microcirculation 
 
III Normal entry and exit of contrast 
medium from microcirculation. 
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The technique and the delay of the PCI can potentially 
have a positive effect on NRp. The minimally invasive 
strategy (MIMI) consists of deferring stenting after 
reperfusion and performing it following several days of 
antithrombotic therapy, which could potentially limit the 
possibility of distal embolization after stent deployment. 
However such a strategy has not until now been shown to 
be effective regarding the infarct size or mortality and is 
not recommended by current guidelines.12,13 The most 
widespread technique is direct stenting of a well-defined 
lesion underlying a thrombotic occlusion in order to entrap 
potentially embolic material, despite the fact that its 
evidence base is limited.13 
Post-conditioning represents a promising new concept 
with the ambition to decrease reperfusion injury.  This 
refers to the activation of intracellular protective 
mechanisms by inducing ischemia in a vascular territory in 
the setting of MI as an additional potential strategy to 
prevent reperfusion injury associated with no-reflow. 
Mechanical post-conditioning has been shown to 
significantly decrease the extent of NRp.14,15 Ischemic 
post-conditioning in this context means repeated balloon 
occlusions of an infarct related artery and evidence in 
support of this technique is strong in experimental animal 
models but also in a recent randomized study in selected 
patients with MI.16 Remote ischemic conditioning during 
evolving ST-elevation MI has been shown to increase  
myocardial salvage. It consists of intermittent arm 
ischemia through four cycles of 5-min inflation and 5-min 
deflation of a blood-pressure cuff during transport for the 
hospital before primary PCI and has as most probable 
mechanism of action the activation of mitochondrial 
intracellular pathways that facilitate preconditioning.17 
The β-blockers use early after MI has been questioned  but 
could regain potential after a recent demonstration of 
benefit regarding the infarct size of a bolus of metoprolol 
at the moment of reperfusion.18,19 Finally after the 
repetitive failures of erythropoietin still some hope rests 
upon cyclosporine A which has been shown to be effective 
in reducing infarct size in a pilot study when administrated 
immediately before reopening of the culprit artery and is 
actually the object of further research.20,21 
 
- Therapeutic measures: Since the NRp is installed the 
therapeutic maneuvers are limited. The intracoronary 
administration of vasodilators (most commonly adenosine 
and verapamil) to fight against microvascular dysfunction 
is a widespread practice, but has not been definitely shown 
to be effective regarding infarct size.22  Adenosine is 
considered to be a first line drug due to its ease of 
application, short half-life and strong vasoactive 
properties. Also widely used in case of NRp is verapamil 
(an L-type calcium channel antagonist) that acts on both 
vascular smooth muscle cells and conductive tissue, thus 
back-up temporary pacing should be available when it is 
used for intracoronary administration. Apart from 
adenosine and verapamil, papaverine, sodium 
nitroprusside, cyclosporine, streptokinase and epinephrine 
have all been successfully used after the development of 
NRp. Especially intracoronary epinephrine has been 
successfully used and must be considered in patients with 
refractory no-reflow. Each catheterization laboratory must 
have a certain protocol to treat NRp and it is important to 
administer any chosen drug as distally as possible in the 
coronary bed (through microcatheters) in order to act 
specifically on the microcirculation and thus achieve the 
best possible result. 
 
Conclusions 
 
After a myocardial infarction NRp is a strong predictor 
of mortality and is present in more than 50% of cases 
despite apparent successful revascularization. A TIMI III 
flow at the end of the PCI is necessary but not sufficient in 
order to guarantee a good prognosis. The assessment of the 
TMPG and the electrocardiographic ST segment 
resolution are important in order to accurately detect NRp 
even at the presence of TIMI III flow. After the MI the 
performance of a cardiac MRI would be beneficial since 
the presence of no-reflow is even retrospectively detected 
and accounted for prognosis. The treatment of NRp is not 
yet well defined in the guidelines and is currently the 
object of various research efforts. 
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